Doxorubicin (Adriamycin) Licensed by Pfizer

Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

Price Stock Quantity  
In DMSO USD 117 In stock
USD 90 In stock
USD 210 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Doxorubicin (Adriamycin) Chemical Structure

Doxorubicin (Adriamycin) Chemical Structure
Molecular Weight: 579.98

Validation & Quality Control

Customer Reviews(4)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Topoisomerase Inhibitors
    Compare Topoisomerase Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
Targets Topo II [1]
In vitro Doxorubicin, an antibiotic anthracycline, is commonly considered to exert its anti-tumor activity at two fundamental levels, altering DNA and producing free radicals to trigger apoptosis of cancer cells through DNA damage. Doxorubicin can block the synthesis of DNA by intercalating into the DNA strand, and inhibits DNA topoisomerase II (TOP2). Doxorubicin is most effective when cells are rapidly proliferating and expressing high levels of TOP2. Additionally, Doxorubicin can trigger apoptosis by producing ceramide (which prompts apoptosis by activating p53 or other downstream pathways such as JNK), the degradation of Akt by serine threonine proteases, the mitochondrial release of cytochrome c, increased FasL (death receptor Fas/CD95 ligand) mRNA production, and a greater production of free radicals. [2] Pre-treatment with GSNO (nitrosoglutathione) suppresses the resistance in the doxorubicin-resistant breast cancer cell line MCF7/Dx, accompanied by enhanced protein glutathionylation and accumulation of doxorubicin in the nucleus. [3] Doxorubicin induced G2/M checkpoint arrest are attributed to elevated cyclin G2 (CycG2) expression and phospho-modification of proteins in the ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) signaling pathways. [5] Doxorubicin inhibits AMP-activated protein kinase (AMPK), resulting in SIRT1 dysfunction, p53 accumulation, and increased cell death in mouse embryonic fibroblasts (MEFs) and cardiomyocytes, which can be further sensitized by pre-inhibition of AMPK. [6] Doxorubicin elicits a marked heat shock response, and that either inhibition or silencing of heat shock proteins enhance the Doxorubicin apoptotic effect in neuroblastoma cells. Nanomolar Doxorubicin treatment of neuroblastoma cells causes dose-dependent over-ubiquitination of a specific set of proteins in the absence of measurable inhibition of proteasome, and loss of activity of ubiquitinated enzymes such as lactate dehydrogenase and α-enolase, the protein ubiquination patterns of which is similar to those with proteasome inhibitor Bortezomib, indicating that Doxorubicin may also exert its effect by damaging proteins. [8]
In vivo In vivo, Doxorubicin in combination with adenoviral MnSOD (AdMnSOD) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) has the greatest effect in decreasing the volumes of MB231 tumors and prolonging survival of mice. [1] Although its use is limited by the chronic and acute toxic side effects it produces, Doxorubicin is essential in treating breast and oesophageal carcinomas, solid tumours in childhood, osteosarcomas, Kaposi's sarcoma, soft tissue sarcomas, and Hodgkin and non-Hodgkin lymphomas. [2]
Features

Protocol(Only for Reference)

Animal Study: [1]

Animal Models Female athymic nude mice injected s.c. with MB231 cells
Formulation Dissolved in DMSO, and diluted in saline
Dosages 3 mg/kg/day
Administration Delivered intratumorly
Solubility 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sun W, et al. Cancer Res, 2009, 69(10), 4294-4300.

[2] Granados-Principal S, et al. Food Chem Toxicol, 2010, 48(6), 1425-1438.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2014-09-20)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01775475 Not yet recruiting AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Imm  ...more AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma AIDS Malignancy Clinical Trials Consortium|National Cance  ...more AIDS Malignancy Clinical Trials Consortium|National Cancer Institute (NCI)|The EMMES Corporation December 2014 Phase 2
NCT02199184 Not yet recruiting Leukemia M.D. Anderson Cancer Center December 2014 Phase 2
NCT02166463 Not yet recruiting Recurrent/Refractory Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma National Cancer Institute (NCI) November 2014 Phase 3
NCT02186834 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Karyo  ...more H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics, Inc November 2014 Phase 1|Phase 2
NCT02053597 Not yet recruiting Breast Cancer Jules Bordet Institute October 2014 Phase 2

view more

Chemical Information

Download Doxorubicin (Adriamycin) SDF
Molecular Weight (MW) 579.98
Formula

C27H29NO11.HCl

CAS No. 25316-40-9
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms
Solubility (25°C) * In vitro DMSO 100 mg/mL (172 mM)
Water 20 mg/mL (34 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride

Research Area

Customer Reviews (4)


Click to enlarge
Rating
Source Cancer Res 2014 74, 298-308. Doxorubicin (Adriamycin) purchased from Selleck
Method MTT assay
Cell Lines H1299, A549, Hep3B, HT1080, HCT116, MCF7
Concentrations
Incubation Time 48 h
Results Hypoxic (1% O2 ) conditions for 48 hours. The IC50 value for cisplatin or doxorubicin significantly increased under hypoxia in H1299, A549, Hep3B, and HT1080, but did not in HCT116 and MCF7

Click to enlarge
Rating
Source Mol Cancer Ther 2011 10, 1846-56. Doxorubicin (Adriamycin) purchased from Selleck
Method Viability screen
Cell Lines SK-ES-1 cell, A673 cell
Concentrations 0-10000 nM
Incubation Time
Results In both cell lines, SK-ES-1 and A673, Doxorubicin proved to be effective of the 3 agents.

Click to enlarge
Rating
Source PLoS One, 2013, 8(1):e54595.. Doxorubicin (Adriamycin) purchased from Selleck
Method MTT assay
Cell Lines Huh7, THLE2, Hep5B cells
Concentrations 0.016-52 uM
Incubation Time 74 h
Results Cytotoxicity by doxorubicin was measured by MTT assay at varying concentrations on the HCC lines Huh7, THLE2, Hep3B.

Click to enlarge
Rating
Source J Biomed Mater Res Part A 2012 10.1002/jbm.a.34064. Doxorubicin (Adriamycin) purchased from Selleck
Method Release experiment
Cell Lines N.A.
Concentrations 0.25mg/mL
Incubation Time 2-10 h
Results Doxorubicin was loaded by equilibrium partitioning in the following manner: a stock solution of doxorubicin was prepared in 2 wt % DMSO in 1 PBS (pH 7.4) at a concentration of 0.25 mg/mL. A 5 mg/mL concentration of crushed particles (75–150 um) of P(MAA-g-EG) or P(MAA-g-EG) containing PMMA nanoparticles to doxorubicin stock solution was allowed to stir slowly for 2 h.

Product Citations (18)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Topoisomerase Products

Recently Viewed Items

Tags: buy Doxorubicin (Adriamycin) | Doxorubicin (Adriamycin) ic50 | Doxorubicin (Adriamycin) price | Doxorubicin (Adriamycin) cost | Doxorubicin (Adriamycin) solubility dmso | Doxorubicin (Adriamycin) purchase | Doxorubicin (Adriamycin) manufacturer | Doxorubicin (Adriamycin) research buy | Doxorubicin (Adriamycin) order | Doxorubicin (Adriamycin) mouse | Doxorubicin (Adriamycin) chemical structure | Doxorubicin (Adriamycin) mw | Doxorubicin (Adriamycin) molecular weight | Doxorubicin (Adriamycin) datasheet | Doxorubicin (Adriamycin) supplier | Doxorubicin (Adriamycin) in vitro | Doxorubicin (Adriamycin) cell line | Doxorubicin (Adriamycin) concentration | Doxorubicin (Adriamycin) nmr
Contact Us